Fact.MR – A Market Research and Competitive Intelligence Provider: Chemotherapy-induced nausea and vomiting treatment options are in high demand due to the rising prevalence of cancer and increased adherence to chemotherapy medications.
Injectable CINV Treatment to Hold 66% of the Chemotherapy-Induced Nausea and Vomiting Treatment Market Share
The Fact.MR market study on chemotherapy-induced nausea and vomiting (CINV) treatment market highlights key developments across various segments including form, drug class, emetogenic risk, and distribution channels. The study projects hospitals for CINV treatment to remain the fastest-growing distribution channel.
Fact.MR – A Market Research and Competitive Intelligence Provider: Chemotherapy-induced nausea and vomiting (CINV) treatment options are in high demand due to the rising prevalence of cancer and increased adherence to chemotherapy medications. Given this, Fact.MR forecasts a positive 6% CAGR for the global chemotherapy-induced nausea and vomiting treatment market, reaching US$ 5.7 billion in 2031.
Chemotherapy side effects such as anaemia, sore mouth, nausea, vomiting, and hair loss are prevalent and have a significant influence on patients’ everyday lives, leading in a strong need for CINV treatment options.
Cancer is one of humanity’s greatest social and economic burdens, according to the World Health Organization (WHO). As the number of cancer diagnoses rises, so does the number of patients who require chemotherapy.
Get Sample Copy With Impact Analysis Of COVID-19 Of Market Report
https://www.factmr.com/connectus/sample?flag=S&rep_id=6867
According to GLOBOCAN, roughly 19.3 million new cancer cases will be diagnosed in 2020, and around 10 million people will die from cancer. Furthermore, by 2040, it is estimated that 28.4 million additional cancer cases will be diagnosed.
Similarly, around 4 million cancer patients receive chemotherapy or radiotherapy each year, making it one of the most extensively used cancer treatments. CINV is a side effect that affects about 70% to 80% of people who are having chemotherapy treatment.
The availability of combination treatments for treating chemotherapy-induced nausea and vomiting, as well as constant improvements in drug delivery systems, are boosting market growth.
Market players are investing in research and development to provide more effective and accessible solutions in order to meet the rising demand. This points to the market’s profitable growth possibilities in the future decade.
According to Fact.MR, the United States is expected to lead the North American chemotherapy-induced nausea and vomiting treatment market by 2031, accounting for 86% of regional sales. Through 2031, sales of chemotherapy-induced nausea and vomiting treatment will be boosted by the presence of prominent market competitors and well-established healthcare infrastructure.
“Growing incidence of cancer and surge in patients undergoing chemotherapy treatments and availability of combination therapies are anticipated to drive market growth over the coming years,” says a Fact.MR analyst.
Key Takeaways:
- By form, injectables hold over 66% value share of the global market.
- Based on drug class, 5-HT3 receptor antagonists to dominate with accounting for 42% market share.
- Based on emetogenic risk, the highly emetogenic chemotherapy (HEC) segment accounts for largest share of 63%.
- By distribution channel, hospitals dominate the market with a value share of 36%, while on the other hand, cancer research institutes are projected to grow at a CAGR of 4.5%.
- By region, North America leads the global CINV treatment market with a value share of 44%.
Growth Drivers:
- In the coming years, the easy availability of chemotherapy-induced nausea and vomiting treatment drugs through online pharmacies will boost sales.
- Drug approvals on a fast track will enhance sales of chemotherapy-induced nausea and vomiting treatments.
- Treatment reimbursement plans in developed countries will make it easier to sell medications and equipment to treat chemotherapy-induced nausea and vomiting.
Key Restraints:
- Access and availability regulations for CINV medicines may stifle market expansion.
- The loss of generic medicine brand exclusivity could stymie sales of CINV therapy solutions.
To learn more about Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market, you can get in touch with our Analyst at
https://www.factmr.com/connectus/sample?flag=AE&rep_id=6867
Competitive Landscape
The global CINV treatment market is characterized by the presence of both established and new competitors. The growing demand for chemotherapy-induced nausea and vomiting treatment has prompted important competitors to enter the market with new and innovative solutions.
To increase their product portfolios and acquire maximum market share, leading manufacturers of drugs for the treatment of chemotherapy-induced nausea and vomiting are focusing on acquisitions.
- In January 2019, GSK finalised the acquisition of TESARO Inc., an oncology-focused biopharmaceutical business for an estimated cash consideration of US$ 5.1 billion.
- In July 2019, Pfizer Inc. bought Array BioPharma Inc., a pharmaceutical firm based in the United States. This acquisition is expected to boost the company’s creative biopharmaceutical business and help meet unmet medical requirements for diseases including cancer and other rare diseases.
Leading Players in the Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Include:
- Kyowa Kirin, Inc.
- Pfizer Inc.
- GlaxoSmithKline plc.
- AbbVie Inc. (Allergan plc)
- Merck & Co., Inc.
- Bausch Health Companies Inc.
- Novartis AG
- Ono Pharmaceutical Co., Ltd.
- Camurus AB
- Heron Therapeutics, Inc.
More Valuable Insights on Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market
Fact.MR provides an unbiased analysis of chemotherapy-induced nausea and vomiting (CINV) treatment market, presenting historical demand data (2016-2020) and forecast statistics for the period from 2021-2031. The study divulges compelling insights on the global chemotherapy-induced nausea and vomiting (CINV) treatment market with a detailed segmentation on the basis of:
Form:
- Injectables
- Oral
- Transdermal Patches
Drug Class:
- 5-HT3 Receptor Antagonists
- Neurokinin-1 Receptor Antagonists
- Corticosteroids
- Cannabinoids
Emetogenic Risk:
- Highly Emetogenic Chemotherapy (HEC)
- Moderately Emetogenic Chemotherapy (MEC)
- Low Emetogenic Chemotherapy (LEC)
Distribution Channel:
- CINV Hospitals
- Cancer Research Institute
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- MEA
Key Questions Covered in the Market Report
- The report offers insight into chemotherapy-induced nausea and vomiting treatment market demand outlook for 2021-2031
- The market study also highlights projected sales growth for chemotherapy-induced nausea and vomiting treatment market between 2021 and 2031
- Chemotherapy-induced nausea and vomiting treatment market survey identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry
- Chemotherapy-induced nausea and vomiting treatment market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, joint ventures, collaborations or partnerships, and others
Explore Fact.MR’s Coverage on the Healthcare Domain –
Oral Chemotherapy Market Forecast - The increase in the number of cancer patients is a major factor driving the global growth of the oral chemotherapy market. In addition, doctors’ preference for oral chemotherapy over intravenous oral chemotherapy is expected to boost revenue growth in the oral chemotherapy market.
Cancer Profiling Market Analysis - The global cancer profiling market is predicted to grow significantly, as the demand for precision medicine and high-quality oncology care growsSmart technology, nanomedicine, and automation are being used efficiently by key solution providers to speed up diagnostic processes.
Cancer Immunotherapy Market Trends - According to a recent analysis issued by Fact.MR, there is a disparity in the distribution of cancer immunotherapy between developing and developed countries. Individuals in the United States are more likely to seek cancer diagnostics as a result of the high frequency of knowledge-based awareness efforts
Cancer Biomarkers Market Analysis - Governments’ aggressive funding initiatives for cancer diagnostics are expanding the market for cancer biomarkers. Demand for cancer biomarkers will be bolstered by factors such as the availability of low-cost, non-invasive prognosis.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
Mahendra Singh
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Source: Fact.MR